We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why
Read MoreHide Full Article
Invivyd’s (IVVD - Free Report) shares have seen a significant rise, owing to the company's encouraging progress in the development of VYD222, its leading investigational monoclonal antibody candidate.
The company is evaluating VYD222 in a phase I dose-ranging study to prevent symptomatic COVID-19 in immunocompromised people. The study is being conducted in Australia with an aim to assess the safety, tolerability and serum virus neutralizing activity of VYD222 in healthy adults.
Initial data from the study revealed that a single administration of VYD222 was well tolerated across all tested dose levels(1500 mg, 2500 mg and 4500 mg) with no reports of serious adverse events. Additionally, serum samples from all dose levels exhibited robust neutralization activity against the Omicron XBB.1.5 variant by day seven.
Shares of Invivyd rallied 18.3% in the past three months against the industry’s 3.5% decline.
Image Source: Zacks Investment Research
Based on the above data, the company plans to initiate a CANOPY study with 4500 mg dose of VYD222. Although all the doses of VYD222 have shown potential against symptomatic COVID-19 in the phase I study, the 4500mg dose showed the highest levels of serum neutralizing titers against Omicron XBB.1.5 variant. This decision was influenced by the FDA's recommendation for a cautious benchmark of serum neutralizing titers. The company believes that the 4500 mg dose could provide prolonged protection and guard against any weakening of the neutralizing effect as the SARS-CoV-2 virus evolves over time.
The CANOPY study will enroll around 750 participants across two cohorts. While cohort A will focus on immunocompromised individuals using serum neutralizing titers as the primary efficacy endpoint, cohort B will assess safety and tolerability in individuals who are at risk of SARS-CoV-2 exposure. Data from this study will further support the submission for a potential emergency use authorization of VYD222. Initial data from the study is expected by 2023-end.
VYD222 was developed based on another experimental treatment called adintrevimab, which has been proved to be safe and effective in a previous clinical study for preventing and treating COVID-19.
In the past 90 days, the Zacks Consensus Estimate forANI Pharmaceuticals’ earnings has gone up from $3.31 per share to $3.73 for 2023. The bottom-line estimate has risen from $4.32 to $4.35 for 2024 during the same time frame. Shares of the company have rallied 39.6% in the past three months.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise 91.56%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to $2.77 for 2024 during the same time frame. Shares of the company have lost 2.1% in the past three months.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 39.8% in the past three months.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why
Invivyd’s (IVVD - Free Report) shares have seen a significant rise, owing to the company's encouraging progress in the development of VYD222, its leading investigational monoclonal antibody candidate.
The company is evaluating VYD222 in a phase I dose-ranging study to prevent symptomatic COVID-19 in immunocompromised people. The study is being conducted in Australia with an aim to assess the safety, tolerability and serum virus neutralizing activity of VYD222 in healthy adults.
Initial data from the study revealed that a single administration of VYD222 was well tolerated across all tested dose levels(1500 mg, 2500 mg and 4500 mg) with no reports of serious adverse events. Additionally, serum samples from all dose levels exhibited robust neutralization activity against the Omicron XBB.1.5 variant by day seven.
Shares of Invivyd rallied 18.3% in the past three months against the industry’s 3.5% decline.
Image Source: Zacks Investment Research
Based on the above data, the company plans to initiate a CANOPY study with 4500 mg dose of VYD222. Although all the doses of VYD222 have shown potential against symptomatic COVID-19 in the phase I study, the 4500mg dose showed the highest levels of serum neutralizing titers against Omicron XBB.1.5 variant. This decision was influenced by the FDA's recommendation for a cautious benchmark of serum neutralizing titers. The company believes that the 4500 mg dose could provide prolonged protection and guard against any weakening of the neutralizing effect as the SARS-CoV-2 virus evolves over time.
The CANOPY study will enroll around 750 participants across two cohorts. While cohort A will focus on immunocompromised individuals using serum neutralizing titers as the primary efficacy endpoint, cohort B will assess safety and tolerability in individuals who are at risk of SARS-CoV-2 exposure. Data from this study will further support the submission for a potential emergency use authorization of VYD222. Initial data from the study is expected by 2023-end.
VYD222 was developed based on another experimental treatment called adintrevimab, which has been proved to be safe and effective in a previous clinical study for preventing and treating COVID-19.
Invivyd, Inc. Price and Consensus
Invivyd, Inc. price-consensus-chart | Invivyd, Inc. Quote
Zacks Rank & Stocks to Consider
Invivyd currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are ANI Pharmaceuticals (ANIP - Free Report) , Annovis Bio (ANVS - Free Report) and Corcept Therapeutics (CORT - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate forANI Pharmaceuticals’ earnings has gone up from $3.31 per share to $3.73 for 2023. The bottom-line estimate has risen from $4.32 to $4.35 for 2024 during the same time frame. Shares of the company have rallied 39.6% in the past three months.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise 91.56%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to $2.77 for 2024 during the same time frame. Shares of the company have lost 2.1% in the past three months.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 39.8% in the past three months.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.